HDAC6-IN-63

HDAC6-IN-63 (Compound 7) is an orally active inhibitor of HDAC6 with an IC50 of 145 nM. It suppresses the expression of Sp1 and RAD51, inducing caspase-dependent apoptosis. HDAC6-IN-63 exhibits antitumor activity and enhances the sensitivity of Etoposide and Gemcitabine by inhibiting homologous recombination and non-homologous end joining (NHEJ) pathways involved in DNA double-strand break (DSB) repair, promoting synergistic cell death in NSCLC cells. This compound is applicable for chemotherapy research in cancers such as NSCLC.